
Pfizer hands LianBio $70M to tag along Perceptive's China play, with an eye to beefing up regional portfolio
When Perceptive unveiled its carefully curated syndicate for LianBio’s $310 million Series A, Pfizer stood out as the only pharma amid a marquee group of VCs. It turns out that the drugmaker wasn’t only looking to share the fruits of LianBio’s labor, it also wants to get down into the trenches.
Pfizer has put an additional $70 million on the table for LianBio — which Perceptive set out to shape into a “best-in-class sourcing and development engine” in China — to in-license programs that they can then co-develop. If a drug reaches the market, Pfizer will be first in line to negotiate for standalone commercial deals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.